SGS Awarded cGMP Accreditation for New Italian Analytical Laboratory
SGS Life Science Services has been awarded cGMP accreditation for its newly added analytical laboratory, at its Livorno, Italy facility.
SGS’s first dedicated life science laboratory in Italy, the new lab will focus on analytical quality control testing, IT compliance and validation, and complements the existing service offer at the Livorno site, which provides facilities qualification, calibration and validation services, and an analytical chemistry laboratory which opened in 2013.
The 1085m² laboratory employs 25 staff, is also ISO 9001 accredited, and completes the SGS Life Science Services offering for the Italian market. cGMP accreditation enables the Livorno GMP laboratory to demonstrate, on behalf of it clients, whether or not individual batches of their raw materials, or of their regulated product, are manufactured according to the highest quality standards.
“The investment in the new laboratory and its cGMP accreditation adds significantly to our existing offer and will enable us to conveniently serve the microbiological and chemical testing needs of our clients in the important Italian market, where many multinational pharmaceutical firms and API manufacturers are located,” commented Marco Benvenuti, Business Manager, SGS Life Science Services.
Frédéric Gaussens, Vice President Global Strategy and Business Development, SGS added: “The Livorno facility further strengthens our global footprint in Europe and provides great synergies with our current method development, equipment and instrument validation and calibration services. This investment is key to our ongoing expansion programme, both strategically and geographically.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance